RedHill's opaganib receives FDA rare pediatric disease designation for childhood cancer
RedHill Biopharma (NASDAQ:RDHL) announced that the U.S. Food and Drug Administration has granted rare pediatric disease designation to its investigational asset, opaganib, for the treatment of neuroblastoma, a type of cancer that primarily affects infants and young children.
The decision expands the regulatory support framework for the oral, small molecule drug candidate, which already holds an active FDA orphan drug designation for the same pediatric oncology indication.
The rare pediatric disease program specifically targets serious or life-threatening conditions that primarily affect individuals from birth to 18 years of age.
By securing this latest status, RedHill may become eligible to receive a Priority Review Voucher from the FDA if opaganib gains formal regulatory approval for neuroblastoma, subject to certain conditions.
These vouchers can either be redeemed by the developer to accelerate the review timeline of a subsequent corporate product application to six months or sold to third-party pharmaceutical firms in the secondary market.
Beyond the voucher potential, the dual designations offer a spectrum of development incentives designed to reduce financial and operational friction for specialized clinical pipelines.
If approved by the FDA, the designations grant RedHill a potential seven-year window of market exclusivity for opaganib in the neuroblastoma indication.
Additional programmatic benefits include comprehensive waivers for prescription drug user fees, specialized tax credits for qualified clinical testing expenses, and access to expedited regulatory development and review timelines.
Opaganib is a first-in-class selective inhibitor targeting sphingosine kinase-2 (SPHK2).
The host-directed agent is designed to disrupt multiple operational pathways within malicious cell structures, simultaneously inducing cell death and autophagy while mitigating unchecked replication.
In addition to its pediatric oncology track, RedHill is currently evaluating opaganib across multiple developmental pipelines, including adult solid tumors, viral pathogens such as the Ebola virus, inflammatory disorders, and gastrointestinal acute radiation syndrome.
